Li Liu

发表

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Lung-Ji Chang, Shih-Ting Tsao, Huyong Zheng, 2016 .

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Ying Cheng, Dong Wang, Yuankai Shi, 2020 .

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

Guoan Chen, Ying Cheng, Wei Li, 2020, Journal of Hematology & Oncology.

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma

Yuankai Shi, Depei Wu, X. Ke, 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.

P. LoRusso, J. Soria, H. Burris, 2015, The oncologist.

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

J. Jorgensen, M. Duvic, Youn H. Kim, 2015, Blood.

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma

K. Punie, P. Schöffski, O. Bechter, 2016, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Z. Ge, Yuankai Shi, Liping Xie, 2021, Journal of Hematology & Oncology.

Safety, Clinical Activity and Pharmacokinetics of Alflutinib (AST2818) in Advanced NSCLC Patients with EGFR T790M Mutation.

Jian Feng, D. Zhong, Yuankai Shi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

P. LoRusso, M. Stein, J. Mehnert, 2018, Investigational New Drugs.

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

D. Mutch, J. Wheler, A. Traynor, 2017, The oncologist.

Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study

W. Xu, Z. Cai, Jing Liu, 2020, Scientific Reports.

Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study

Kunyuan Wang, Yun Zhu, Ya-bing Guo, 2021, Journal for ImmunoTherapy of Cancer.

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.

Ying Cheng, Dong Wang, Yuankai Shi, 2021, The Lancet. Respiratory medicine.

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

S. Piha-Paul, S. Welch, V. Subbiah, 2017, Investigational New Drugs.